trial · primary record
Belantamab mafodotin
Myeloma Multiple
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 94 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide. |
| Registry ID | NCT05091372 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:20.067Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05091372
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.